John Ternus Signals Apple’s Future with Product-First AI Strategy 
Want to cut your energy bills? Here’s how five experts are doing it 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
NEW YORK, Feb. 27, 2017 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Innocoll Holdings plc securities (NASDAQ:INNL) from November 3, 2016 through December 29, 2016, both dates inclusive (the “Class Period”) of the important March 27, 2017 lead plaintiff deadline in first-filed class action commenced by the Rosen Law Firm. The lawsuit seeks to recover damages for Innocoll investors under the federal securities laws.
To join the Innocoll class action, go to http://www.rosenlegal.com/cases-1019.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Innocoll’s New Drug Application (“NDA”) submission to the FDA in October 2016 for XARACOLL was incomplete; (2) due to the incomplete NDA submission, XARACOLL would not be approved in 2017 as investors were led to believe; and (3) as a result, Defendants’ statements about Innocoll’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 27, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1019.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com
